Quest for discovering novel CDK12 inhibitor
Authors:
- Abhijit DebnathADAbhijit Debnath
- Rajesh Kumar SinghRSRajesh Kumar Singh
- Rupa MazumderRMRupa Mazumder
- Avijit MazumderAMAvijit Mazumder
- Shikha SrivastavaSSShikha Srivastava
- Hema ChaudharyHCHema Chaudhary
- Saloni MangalSMSaloni Mangal
- Jahanvi SanchitraJSJahanvi Sanchitra
- Pankaj Kumar TyagiPankaj Kumar Tyagi
- Sachin Kumar SinghSSSachin Kumar Singh
- Anil Kumar SinghASAnil Kumar Singh
- 19 December 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 45 (1) , 1-21
Abstract
CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology. Targeting CDK12 offers a promising strategy to develop therapy. Various monoclonal antibodies have drawn wide attention, but they are expensive compared to small-molecule inhibitors, limiting their accessibility and affordability for patients. Consequently, this research aims to identify effective CDK12 inhibitors using comprehensive high-throughput virtual screening. RASPD protocol has been employed to screen three different databases against the target followed by drug-likeness, molecular docking, ADME, toxicity, Consensus molecular docking, MD Simulation, and in-vitro studies MTT assay. The research conducted yielded one compound ZINC11784547 has demonstrated robust binding affinity, favorable ADME features, less toxicity, remarkable stability, and cytotoxic effect. The identified compound holds promise for promoting cancer cell death through CDK12 inhibition.Keywords
All Related Versions
Funding Information
- Department of Health Research, Govt. of India (M-48/0179, R.12014/57/2022-HR)
This publication has 79 references indexed in Scilit:
- Towards Effective Consensus Scoring in Structure-Based Virtual ScreeningInterdisciplinary Sciences: Computational Life Sciences, 2022
- Why 90% of clinical drug development fails and how to improve it?Acta Pharmaceutica Sinica B, 2022
- CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancerCancer Letters, 2020
- Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinomaBiochemical and Biophysical Research Communications, 2019
- Structure‐Based Design of Selective Noncovalent CDK12 InhibitorsChemMedChem, 2017
- Diagnosis and treatment of Ewing sarcoma of the bone: a review articleJournal of Orthopaedic Science, 2015
- CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR dataJournal of Computational Chemistry, 2013
- MDAnalysis: A toolkit for the analysis of molecular dynamics simulationsJournal of Computational Chemistry, 2011
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004